UNSPSC 51292929: Trimipramine maleate

This classification denotes a tricyclic antidepressant with the molecular formula C20H26N2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 269K6498LD, chemically known as 5,6-dihydro-n-(3-(dimethylamino)propyl)-11h-dibenz(b,e)azepine but more generally known as trimipramine maleate, which bears US NIH Compound Identifier 3696. European Medicines Agency schedules Trimipramine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04977MIG.

Most nations, for tariff and trade purposes, schedule trimipramine maleate under HS 29339930 and SITC 51577. As of Q4 2014, TRIMIPRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Trimipramine maleate bears US NLM identifiers UMLS ID C0728956 and NCI Concept Code C47773. SMILES: CC(CN1C2CCCCC2CCC3C1CCCC3)CN(C)C.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51292929 Trimipramine maleate is a Commodity code that nominally covers a specific pharmaceutical product, but the recent state and local procurement activity under this code shows a material mismatch with its abstract scope. The single identified recent opportunity — Seminole County, Florida's IFB 60459723LAS — solicits naloxone and safe drug deactivation systems, which fall outside the trimipramine maleate category entirely. The source provides no evidence of recent state or local solicitations actually purchasing trimipramine maleate or other pharmaceutical products aligned with the code's nominal name. The mismatch suggests either a tagging error in the state procurement system or limited use of this code for its intended commodity.

No recent state or local opportunities support a reliable characterization of issuing-body mix, geographic concentration, or market activity under UNSPSC 51292929. The single record in the recent-opportunities block is unrelated to trimipramine maleate and does not establish a pattern of procurement under this code. Businesses evaluating this code should treat it as showing no actionable current activity and verify whether the code is routinely used by state and local health or pharmaceutical procurement offices before investing in pursuit strategy.